Cadrenal’s CAD-1005 Improves Glycemic Control in Obesity Models, Reduces HIT Thrombotic Events
Cadrenal Therapeutics highlighted preclinical data showing oral CAD-1005 improved glycemic control, reduced pancreatic β-cell loss and inflammatory cell infiltration in adipose and pancreatic tissues in obesity and Type 2 diabetes models. Phase 2 trial of CAD-1005 for suspected HIT showed a reduction in thrombotic events.
1. 12-LOX Inhibition Mechanism
Cadrenal’s CAD-1005 is a first-in-class small molecule that selectively inhibits 12-lipoxygenase, an enzyme overexpressed in adipose tissue and pancreas of obese and diabetic subjects. By blocking 12-LOX activity, CAD-1005 aims to interrupt pro-inflammatory signaling pathways that impair insulin sensitivity and promote β-cell dysfunction.
2. Preclinical Efficacy in Obesity and Diabetes Models
In animal models of obesity and Type 2 diabetes, oral administration of CAD-1005 improved blood glucose regulation, preserved pancreatic β-cell mass and lowered pro-inflammatory cytokine levels in adipose and pancreatic tissues. Adipocyte function was restored through reduced macrophage recruitment, demonstrating dual metabolic and anti-inflammatory benefits.
3. Phase 2 HIT Trial Outcomes
CAD-1005 is also under evaluation for suspected heparin-induced thrombocytopenia. Results from a Phase 2 trial showed a measurable decline in thrombotic events among treated patients without increased bleeding, supporting its potential as a targeted therapy for immune-mediated clotting disorders.
4. Future Development and Pipeline
Following the December 2025 acquisition of the 12-LOX portfolio, Cadrenal is advancing CAD-1005’s clinical development for HIT while exploring potential trials in metabolic inflammation. A next-generation oral candidate, CAD-2000, is in preclinical development as the company expands its pipeline in both thrombotic and chronic inflammatory indications.